AbbVie, Teneobio partner on Multiple Myeloma
AbbVie and Teneobio announced a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
More News: Myeloma | Pharmaceuticals